A new antibiotic from Calvert Health could be around the same time as an antihistaminoid medicine, an industry insider said on Friday.
The industry source told Reuters the drug, which is being developed by a pharmaceutical company, could be in stores as early as the first quarter of 2018.
That would make it the latest antihistamine product to enter the market in the last few years.
In August, Johnson & Johnson and Roche announced a joint venture to create a new drug for chronic back pain.
It is the latest in a series of products developed by the joint venture.
Johnson &.; Johnson and its joint venture partner Roche have teamed up on several antihistammoid and antihistine medicines.
The new product could be a combination of the two drugs, according to the source, who spoke on condition of anonymity.
The drug could have a shelf life of two months or longer, the source said.
It would be the latest antibiotic to be developed in the joint Venture, which has already developed drugs to treat antibiotic-resistant infections.